Additional Coverage:
- Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen (cnbc.com)
Eli Lilly Unveils New Multi-Dose Zepbound Pen, Aiming for Enhanced Patient Convenience
Indianapolis, IN – Eli Lilly has announced the launch of a new multi-dose pen for its popular obesity medication, Zepbound. The innovative KwikPen offers a month’s worth of doses in a single device, potentially streamlining the treatment process for many patients.
Previously, individuals prescribed Zepbound utilized a new single-dose auto-injector each week, or drew medication from single-dose vials into a syringe for self-injection. The introduction of the KwikPen aims to provide a more convenient alternative by consolidating four weekly doses into one device.
The new multi-dose pen is now available for cash-paying patients through Lilly’s direct-to-consumer platform, LillyDirect, with prices starting at $299 per month for the lowest dose level.
This strategic rollout comes as Eli Lilly continues to capitalize on the remarkable success of Zepbound, which has seen explosive demand since its market debut in late 2023. LillyDirect has been instrumental in the drug’s growth, and the addition of this new formulation on the platform is anticipated to further attract patients.
Zepbound’s rapid expansion has allowed Eli Lilly to capture a significant share of the weight loss drug market, outpacing competitor Novo Nordisk. In the company’s fourth quarter, Zepbound generated an impressive $4.2 billion in U.S. revenue, marking a 122% increase year-over-year.
Eli Lilly confirmed that the U.S. Food and Drug Administration (FDA) has approved a label expansion for Zepbound to include the multi-dose device. The KwikPen technology is already well-established, being utilized for other Lilly medications, including the widely used diabetes drug, Mounjaro.
“As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines,” stated Ilya Yuffa, president of Lilly USA and Global Customer Capabilities, in a company release.